{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:56:23Z","timestamp":1758635783459},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Unlabeled and radiolabeled anti-CD20 monoclonal antibodies have had a significant impact in the care of patients with follicular lymphoma (FL) over the past decade. More recently, bendamustine has demonstrated activity in refractory FL, and has been explored as initial therapy and in novel combinations. Whereas outcomes for this patient population have significantly improved, there remains substantial unmet need for patients who require more effective and better-tolerated therapies. Novel anti-CD20 antibodies and other immunotherapies against different B-cell antigens are under active investigation. The proteosome inhibitor bortezomib and the immunomodulatory agent lenalidomide have demonstrated single-agent activity and are currently in randomized trials. Other novel compounds have demonstrated activity in broad-based clinical studies in B-cell malignancies. However, considerable challenges remain in efficiently demonstrating which patient subsets can benefit from these novel compounds and which combinations may have the greatest clinical benefit in further improving outcomes for patients with FL.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.259","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"259-264","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Novel Agents for Follicular Lymphoma"],"prefix":"10.1182","volume":"2010","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[{"name":"Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Center for Lymphoma and Myeloma, and Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111709451787100_B1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"2019111709451787100_B2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"2019111709451787100_B3","first-page":"114","article-title":"Ofatumumab, a human Mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC [abstract 1725]","author":"Craigen","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B4","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"2019111709451787100_B5","first-page":"114","article-title":"Evaluation of ofatumumab, a vovel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract 935]","author":"Hagenbeek","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B6","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111709451787100_B7","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin's lymphoma: phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B8","first-page":"114","article-title":"Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies [abstract 3757]","author":"Negrea","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B9","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"2019111709451787100_B10","first-page":"114","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ non-Hodgkin lymphoma (NHL) [abstract 1704]","author":"Salles","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B11","first-page":"114","article-title":"A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed\/refractory CD20+ malignant disease [abstract 934]","author":"Sehn","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B12","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"key":"2019111709451787100_B13","first-page":"106","article-title":"Anti-CD20 monoclonal sntibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab\u00ae [abstract 348]","author":"Weiner","year":"2005","journal-title":"Blood"},{"key":"2019111709451787100_B14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"2019111709451787100_B15","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B16","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111709451787100_B17","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B18","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy qith the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B19","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"key":"2019111709451787100_B20","first-page":"27","article-title":"Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma [abstract 8571]","author":"Baum","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B21","first-page":"27","article-title":"A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL [abstract 3017]","author":"Andritsos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.iy.12.040194.001355","article-title":"Assembly, transport, and function of MHC class II molecules","volume":"12","author":"Cresswell","year":"1994","journal-title":"Ann Rev Immunol"},{"key":"2019111709451787100_B23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J Exp Med"},{"key":"2019111709451787100_B24","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1073\/pnas.052703299","article-title":"Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity","volume":"99","author":"Matza","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111709451787100_B25","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","article-title":"Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies","volume":"104","author":"Stein","year":"2004","journal-title":"Blood"},{"key":"2019111709451787100_B26","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B27","first-page":"106","article-title":"Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL [abstract 2435]","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"2019111709451787100_B28","first-page":"112","article-title":"FLIPI score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R] [abstract 1003]","author":"Czuczman","year":"2008","journal-title":"Blood"},{"issue":"5891","key":"2019111709451787100_B29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"2019111709451787100_B30","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","article-title":"Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20\/CD22 antibodies in lymphoma","volume":"113","author":"Rossi","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B31","first-page":"114","article-title":"Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent\/refractory follicular or \u2018aggressive\u2019 lymphoma [abstract 584]","author":"Dang","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B32","first-page":"114","article-title":"Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed\/refractory B-cell non-Hodgkin's lymphoma (NHL) [abstract 585]","author":"Younes","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B33","first-page":"26","article-title":"Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: results at high cumulative doses of 90Y [abstract 8502]","author":"Kraeber-Bodere","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin proteasome pathway is required for processing the NF-\u03baB1 precursor protein and the activation of NF-\u03baB","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"2019111709451787100_B35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","article-title":"Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes","volume":"16","author":"O'Connor","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111709451787100_B39","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B40","first-page":"114","article-title":"Bortezomib added to CVP-R is safe and effective for previously untreated advanced stage follicular lymphoma: a phase II study by the NCIC Clinical Trials Group [abstract 407]","author":"Sehn","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B41","first-page":"114","article-title":"Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim p with relapsed\/refractory indolent and mantle cell lymphomas [abstract 3708]","author":"Gerecitano","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B42","first-page":"114","article-title":"Antitumor activity of MLN9708, a second-generation proteasome inhibitor, in preclinical models of lymphoma [abstract 2724]","author":"Donelan","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B43","first-page":"110","article-title":"Phase 1 single aagent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [abstract 411]","author":"Alsina","year":"2007","journal-title":"Blood"},{"key":"2019111709451787100_B44","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111709451787100_B45","first-page":"24","article-title":"AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features; preliminary results from an ongoing phase I trial [abstract 6605]","author":"James","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B46","first-page":"27","article-title":"An open-label, multicenter, phase II study of AT-101 in combination with rituximab\u00ae in patients with untreated, grade 1\u20132, follicular non-Hodgkin's lymphoma (FL) [abstract 8582]","author":"Kingsley","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B47","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2007-09-113647","article-title":"Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)","volume":"111","author":"Kitada","year":"2008","journal-title":"Blood"},{"key":"2019111709451787100_B48","first-page":"114","article-title":"Phase 1\/2a study of ABT-263 in relapsed or refractory lymphoid malignancies [abstract 1711]","author":"Wilson","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B49","first-page":"114","article-title":"Obatoclax and bortezomib therapy results in disruption of the p53-mediated apoptosis\/autophagy pathway and is associated with potent synergistic anti-tumor activity against rituximab-chemotherapy-sensitive and -resistant B-cell lymphoma [abstract 288]","author":"Hernandez-Ilizaliturri","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B50","first-page":"110","article-title":"A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15\u2013070) in combination with bortezomib in patients with relapsed\/refractory mantle cell lymphoma [abstract 2569]","author":"Goy","year":"2007","journal-title":"Blood"},{"key":"2019111709451787100_B51","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma","volume":"15","author":"Tabe","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111709451787100_B52","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2002-08-2482","article-title":"BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma","volume":"102","author":"Akasaka","year":"2003","journal-title":"Blood"},{"key":"2019111709451787100_B53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.2059","article-title":"A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas","volume":"15","author":"Cerchietti","year":"2009","journal-title":"Nat Med"},{"key":"2019111709451787100_B54","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"key":"2019111709451787100_B55","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"2019111709451787100_B56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma [abstract 1169]","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111709451787100_B57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood.V114.22.1679.1679","article-title":"R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract 1679]","volume":"114","author":"Dutia","year":"2009","journal-title":"Blood"},{"key":"2019111709451787100_B58","first-page":"114","article-title":"A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma [abstract 1714]","author":"Fowler","year":"2009","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/259\/1493199\/bep00110000259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/259\/1493199\/bep00110000259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T14:45:34Z","timestamp":1574001934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/259\/95876\/Novel-Agents-for-Follicular-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.259","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}